Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Servier Expands Its Immuno-Oncology Presence With Sorrento PD-1 Deal

Executive Summary

Servier SA has moved to broaden its immune-oncology pipeline by signing a license and collaboration agreement for the development, manufacture and commercialization of products using Sorrento Therapeutics Inc.'s anti-PD-1 monoclonal antibody (mAb) STI-A1110, adding to its ongoing CAR-T efforts.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q3 2016
Deal Watch: Flagship Ventures Doubles Down On Microbiome
Servier and Cellectis sign $850m cancer collaboration

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register